LyoPlas N - w may be stored at +2°C to +25°C. This opens up new areas of use, particularly in emergency medicine and intensive care. In many situations it can be a great advantage not to have to store a product at -30°C and spend extra time on thawing procedures. Clinical institutions will therefore find that LyoPlas N - w is an attractive and time-saving alternative to classical fresh frozen plasma (FFP); it can be used in the same indications without any restrictions in clinical efficacy (see coagulation parameters).
Since 2007 over 450,000 units of LyoPlas N - w have been brought into circulation. To date, the haemovigilance register of DRK-Blutspendedienst West has not recorded any specific, known plasma side effects in relation to LyoPlas N - w or an increased incidence thereof (haemovigilance).
LyoPlas N - w is particularly compatible because
- residual cells are filtered out during production.
- it contains only plasma from donors who are male or have been tested for leukocyte antibodies, thereby preventing transfusion-related acute lung injury (TRALI).
- it is produced from quarantined plasma that does not contain any additives.
The hospitals and institutions supplied by us have not reported any limitations in the efficacy of LyoPlas N - w as compared to FFP.